A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 13, 2021

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

AK117

Subjects receive AK117 intravenously.

DRUG

Azacitidine

Subjects receive Azacitidine subcutaneously.

Trial Locations (1)

The First Affiliated Hospital，Zhejiang University School of Medicine, Hangzhou